



Technology Transfer

Edmund J. Elder, Jr., Ph.D., R.Ph.
Director
Lenor Zeeh Pharmaceutical Experiment Station



"Technology Transfer"



- Office of Corporate Relations
- University Research Park
- WARF (Wisconsin Alumni Research Foundation)
- Licensing of intellectual property
 - Transferring the results of University applied and direct research to solve real-world problems

Outline

- Introduction to Technology Transfer
- Manufacturing Considerations
 - Facilities
 - Equipment
 - Scale-up
 - (pre-) Validation
- Technology Transfer Guidance
 - *Who is responsible for technology transfer?*
 - *When does it occur during development?*

Definitions

- Technology Transfer
 - Drug Substance manufacturing process transfer
 - Analytical method transfer
 - Drug Product manufacturing process transfer
- Scale-up
 - Increase in batch size from development scale to pilot scale to full scale manufacturing
- Validation
 - Documented evidence that a system is designed to assure that the process consistently performs as it purports to do.

Technology Transfer

The ultimate test of scientific reproducibility:
The successful transfer of production responsibilities
from development scientists to production personnel



eje | June 2009

51st Land O'Lakes

4

When does Tech Transfer occur?

Depending on organization, *frequently!*

- Preformulation
 - Pre-clinical Formulation
 - Phase 1/2a Formulation
 - Phase 2b/3 Formulation
- Development**
- ↓
- Production Support**
- ↓
- Manufacturing/Validation/QC

eje | June 2009

51st Land O'Lakes

5

What Technologies are Transferred?

- Development
 - Chemical Development
 - Active Pharmaceutical Ingredient (API)
 - Analytical Development & Clinical QA
 - Methods & Specifications
 - Product Development
 - Dosage Form Development
 - Manufacturing Process Development
- Manufacturing
 - Drug Substance Manufacturing Site
 - Active Pharmaceutical Ingredient (API)
 - QA / QC
 - Methods & Specifications
 - Drug Product Manufacturing Site
 - Manufacturing Process Validation

Successful Tech Transfer

- Process must be well defined
 - Identify areas of criticality, sensitivity and/or weakness
 - Analyze operational boundaries, risks
- Must be robust in R&D if expected in Production/QC
- Minimize process “improvements”
 - i.e. changes
- Members of Development and Production work jointly during initial run(s)/campaign

21 CFR Subpart F § 211.100(a)

...to assure...

- Identity
- Strength
- Quality
- Purity
- **Functionality**

...of drug product.

What are the challenges?

- **Technological**
 - Facilities
 - Equipment
 - Unit operations/processes
 - Overall process train
 - *no two are the same!*
- **Personnel**
 - Communication across organization
 - Remote sites
 - Historically, differences in mindset:
 - R&D = Creative, responsible for inventing change
 - Process Development = Problem solvers, troubleshooters
 - Production/QC = Detail-oriented, disciplined, observant
 - "Quality by Design" demands innovation throughout!

Linking Material Attributes...

- Excipient **Functionality**
 - *Proposed* USP General Chapter
 - <1059> Excipient Performance
 - Pharmacopeial Forum 33(4), 2007
 - PhEur General Chapter
 - Functionality Related Characteristics (FRCs) of Excipients (5.15)
 - Draft: Pharmeuropa 18(3), 2006
 - Adopted: Council of Europe, Supplement 6.1, Chapter 5.14, PhEur (2007)
- EMEA Committee for Medicinal Products for Human Use, *Guideline on Excipients in the Dossier for Application for Marketing of Medicinal Product*, November 2006
- ICH Q8, *Guideline on Pharmaceutical Development*, November 2005
 - Quality by Design [**QbD**]
- DHHS-FDA, *Pharmaceutical cGMPs for the 21st Century – A Risk-Based Approach*, September 2004

Outline

- Introduction to Technology Transfer
- Manufacturing Considerations
 - Facilities
 - Equipment
 - Scale-up
 - (pre-) Validation
- Technology Transfer Guidance

Manufacturing Site Considerations


- Facility Design
- Equipment
- Management
 - Training
 - Experience
- Documentation
- Interactive Relationship
 - Parent : Child
 - Siblings
 - Peers

eje | June 2009

51st Land O'Lakes

12

Facility Differences



eje | June 2009

51st Land O'Lakes

13

Equipment Differences


- Blenders / Granulators
 - Rate of Shear
 - Geometry
 - Size
- Tablet Presses
 - Compression Mechanism - mechanical, pneumatic
 - Units of Force
 - Direct or Indirect Force Measurement
- Coating Pans
 - Size
 - Air handling system

eje | June 2009

51st Land O'Lakes

14

Capsules



Elder, et. al. , Glaxo Research Institute, AAPS 1993 SERM

eje | June 2009

51st Land O'Lakes

15

Domestic vs. International Manufacturing Considerations

- Regulatory Requirements
 - NDA
 - MAA
 - JNDA
 - NDS (Canada)
- < **ICH** >
 - CTD
- Excipient Specifications
 - USP/NF
 - BP
 - Ph.Eur.
 - JP
 - FCC
 - GRAS
 - WHO
 - FDA Inactive Ingredients Guide

eje | June 2009

51st Land O'Lakes

16

Target Product Profile

- Target disease
- Target patient population
- Target indication(s)
 - Specific level of desired and minimal acceptable safety
 - Specific level of desired and minimal acceptable efficacy
 - Specific level of desired and minimal acceptable tolerability
- Target route of administration
- Target dose and dosing regimen and acceptable range of deviation
 - Course/duration of treatment
- Target drug product presentation and acceptable range of deviation
 - Packaging, Storage conditions, shelf life, etc.
- Target markets & market size
- Target cost and acceptable overage
- Target price and acceptable range

eje | June 2009

51st Land O'Lakes

17

Market Image

- Product Identification
 - Single set of markings to satisfy worldwide regulatory requirements
- Colorants
 - Worldwide Acceptability
 - Titanium Dioxide (White)
 - Iron Oxide Red
 - Iron Oxide Yellow
 - FD&C Blue #2

Effective Process scale-up

- Approach lab process as “scaled-down version of commercial process”
- Understand the unit processes
 - Spray-drying: effect of nozzle, atomization P, flow rate on droplet size, spray pattern, velocity
- Identify critical process parameters
 - Sterile product: mode of sterilization, filtration, stirring rate, shear rate, batch size

What lends to process scalability?

- No change between *type* of equipment
- No significant change between surface-to-volume ratio
- Unit process is scaled up by repetition, not by increase in volume
 - Continuous vs batch mode
- Process less sensitive to time, temperature


Additional Scale-up considerations

especially for Biologicals

- cGMP Scale-up equipment design
- Specs for process control, operator interface
- Contractors and the Request for Proposal process
- Integrating automation
- Installation, Commissioning, Development, FAT
- Equipment, Process, Cleaning Validation
- Maintenance


= long lead times!!!

Scaling up a suspension formulation



Batch size **Biobatch**
10 liters

Mixing time **15 mins**



Commercial
batch 100 liters

45 mins

Are these processes equivalent?

Adapted from Colin R. Gardner, Presentation to Manufacturing Subcommittee of the FDA Advisory Committee for Pharmaceutical Science, Sept 17, 2003


eje | June 2009
51st Land O'Lakes
22

Components of Validation

- DQ
- IQ
- OQ
- PQ
- RQ
- Change Control
- Pre-Validation

- Qualification
- Design
- Installation
- Operational
- Process
- "Re-"
- QbD considerations

eje | June 2009
51st Land O'Lakes
23



- ## Lessons Learned
- Build quality systems early, evolve strategically
 - Provide effective training for a fast-growing workforce; hire, train ahead of curve where possible
 - Understand the chemistry of the system
 - Understand the fundamental phenomena of the process
 - Take advantage of outside expertise
 - Define commercial product early
 - Do not assume everything will work the first time!
 - Beware the law of unintended consequences
 - Put change control procedures in place early
 - **Scale-UP** communication
 - Work with FDA, not against them
 - Track the dynamically changing regulatory picture!
- eje | June 2009 51st Land O'Lakes 25

CQA...

- If you fail to pull a sample at any (non-) critical step of the process...
- That will be the sample that could have identified the cause of your problem.

Softgel Process Steps

- API
- Excipients
- Mixing
- Milling
- Filling
- Drying
- Sizing
- Printing
- Inspection
- Polishing
- Packaging
- Shipping / Distribution

Outline

- Introduction to Technology Transfer
- Manufacturing Considerations
 - Facilities
 - Equipment
 - Scale-up
 - (pre-) Validation
- Technology Transfer Guidance

Technology Transfer Guideline

- Standardized Process
- Minimum Base of Documentation
 - Analytical Methods
 - Active Pharmaceutical Ingredients (APIs)
 - Dosage Forms

ISPE Good Practice Guide, Technology Transfer, 2003



Ministry of Health, Labour and Welfare

Objectives

- To describe information that needs to be compiled...
 - to support manufacture
 - to provide for regulatory filings
- To provide effective approaches for ensuring information is available at the point of use.



Quality of Pharmaceutical Products

- Robust manufacturing processes
 - consistent and predictable operation
 - in accordance with cGMPs
 - facilitate ease of validation
- Extensive information set
 - defines all activities necessary to:
 - manufacture
 - control
 - measure
 - relevant and up-to-date



Definition of Success

- Receiving unit can routinely reproduce
 - product
 - process
 - method
 - against a predefined set of specifications
 - as agreed with the sending and/or development unit
- Regulated Environment
 - Documentation is CRITICAL



Experience & Knowledge Capture

- R&D to Manufacturing
 - formulation and rational
 - pivotal batch data
 - process evolution/history
- Business Factors
 - cost
 - capacity/volume
 - facilities and equipment
 - timelines
 - regulatory requirements
- Site to Site
 - manufacturing process and rational
 - annual product review documentation
 - batch comparison data
 - pivotal batch data
 - clinical, bio, stability, registration
 - batch list and pedigree
 - size, use, etc.



Dosage Form

- API
- Excipients
- Manufacturing Process
- Manufacturing Facility & Equipment
- Packaging/Device Components
- Packaging Operations
- Health, Safety & Environmental
- Qualification and Validation



General Excipient Information

- Functionality
- Manufacturer
- Specifications
- Special Considerations
 - heat, light, moisture, etc.
 - HS&E
- Regulatory Considerations
 - Compendial Status
 - Grade
 - Validation/Qualification of multiple suppliers
 - Drug Master File
 - Residual Solvents / Organic Volatile Impurities
 - BSE / TSE
 - Allowable range of use
 - SUPAC




Excipient Characterization



Characteristic	Oral Solid	Parenteral	Semisolid/ Topical	Liquid	Transdermal	Inhalation
Form/ Morphology	X					X
PS/ PSD	X				X	X
Bulk Density	X					X
Compaction	X					
Solubility	X				X	X
Water Content/ Hygroscopicity/ Moisture Content	X	X	X	X	X	X
pH/ Ionic Strength		X	X	X	X	
Specific Gravity/ Density		X	X	X	X	
Viscosity		X	X	X	X	
Osmolarity		X				
Microbiological Considerations		X	X	X	X	X
Melting Range			X			
Partition Coefficient					X	
Intrinsic Dissolution					X	
Adhesive Properties					X	

Experience & Knowledge Capture

- Critical processing parameters 
- Specifications and rational
 - critical analytical data (release and stability)
- Qualitative and quantitative compositions
 - known differences in suppliers and performance
- Comparison of processing steps and equipment
- Comparison of analytical methods and instrumentation



More Details...

See Extra Slides



Technology Transfer Team

- Core Expertise
 - Product Development
 - Formulation Development
 - Process Development
 - Analytical
 - Device Development
 - Packaging Development
 - Manufacturing
 - Production
 - Manufacturing
 - Packaging
 - Technical Support
 - Engineering
 - Quality Assurance/Control
 - Validation
- Supporting Expertise
 - Regulatory
 - Health/Safety/Environmental
- Line Management Support

eje | June 2009

51st Land O'Lakes

38


Keys to Successful Product Transfer

- Establish trust between development, transfer and manufacturing groups
- Free information exchange
- Communication
- Open mind to diversity and alternate ideas/options
- Develop a standardized transfer policy
 - Define teams
 - Establish information requirements
 - Identify activities and responsibilities
- Identify manufacturing site(s) early in development

eje | June 2009

51st Land O'Lakes

39



Scale Up and Technology Transfer

- Technology transfer and scale-up of pharmaceutical dosage forms must be well controlled and scientifically based
 - Transfer interactions, activities, and documentation must be well defined.
 - Pilot facilities must be constructed and equipped to adequately simulate full scale manufacturing operations.
 - Formulation and components must be well characterized early in development.
 - The manufacturing process must be well characterized and critical process variables must be identified, monitored and controlled during scale-up.
- The ultimate goal of all scale-up and transfer activities is to produce a product meeting all quality standards on a routine basis in production.
 - Adapted from: R.M.Franz, *Glaxo*, ~1992

eje | June 2009 51st Land O'Lakes 41



www.pharmacy.wisc.edu/zstation

eelder@pharmacy.wisc.edu



EXTRA SLIDES

Technology Transfer



Chemical Development Role

- Develop synthetic route & scheme for efficiency, reliability, scalability
- Training of manufacturing staff
- Outline Batch Manufacturing Records
- Identify in-process variables
- Recommend in-process specifications
- Identify critical process variables for validation
- Assist with conducting and documenting validation
- Prepare technology transfer report
- Oversight of initial runs in production
- Assist with troubleshooting production problems
- Key chemistry/chemical engineering contact

Product Development Role

- Develop drug product manufacturing process for efficiency, reliability, scalability
- Training of manufacturing staff
- Outline Batch Manufacturing Records
- Identify in-process variables
- Recommend in-process specifications
- Identify critical process variables for validation
- Assist with conducting and documenting validation
- Prepare technology transfer report
- Oversight of initial runs in production
- Assist with troubleshooting production problems
- Key scientific contact for formulation/process

Analytical Technical Transfer Role

- Has led or contributed to developing **analytical methods** for efficiency, reliability, scalability
- Has managed or assisted initial **methods transfer to QC**
- Assists in preparing **Analytical Test Procedures**
- Trains **QC** staff
- Establishes **RM and product** specs
- Prepares Tech Transfer protocol and report
- Prepares and/or reviews Validation protocols
- Directs **Methods Transfer Validation**
- Troubleshoots **QC** problems
- Key scientific/**QC chemist** contact

eje | June 2009

51st Land O'Lakes

46

Roadblocks

- R&D prima donna syndrome
- Manufacturing fire fighting
- Lack of organizational teamwork
- Band-aid fixes
- Lack of product focus
 - Analytical
 - Packaging
- Physical test methods not validated
 - Dissolution
- Acceptance criteria and responsibility not well defined - commercial vs. development batches

eje | June 2009

51st Land O'Lakes

47



EXTRA SLIDES

Technology Transfer Guidance




Regulatory Factors

- Pre-defined specification
- Adequate facilities and trained staff
- Establishment of protocols and Standard Operating Procedures (SOPs)
- Data




Analytical Methods Transfer

Tests	API	Dosage Form						
		Solids	Parenterals	Inhalation	Semi-solids/ Ointments/ Creams	Liquids/ Suspensions	Transdermals	Ophthalmic
Assay	X	X	X	X	X	X	X	X
Content Uniformity		X	X	X	X	X	X	X
Impurities/ Degradants	X	X	X	X	X	X	X	X
Dissolution/ Release Rate/ Dose Delivery		X		X		X	X	
Identification	X	X	X	X	X	X	X	X
Cleaning Verification	X	X	X	X	X	X	X	X
Microbiological	X	X	X	X	X	X	X	X
Physical Criteria	X			X				



eje | June 2009
51st Land O'Lakes
50

- ## API Active Pharmaceutical Ingredient
- Synthetic Route
 - Form
 - Process Materials
 - Starting Materials
 - Raw Materials
 - Reagents
 - Catalysts
 - Facility & Equipment
 - Health, Safety & Environmental
 - Process
 - Critical Parameters
 - In-process Controls
 - Characterization
 - API & Intermediates
 - Cleaning
 - Reprocessing
 - Packaging
 - Qualification & Validation
- 
-
- eje | June 2009
51st Land O'Lakes
51

BACPAC

Bulk Active post-Approval Changes

- I - Intermediates
- II - Drug Substance
 - (to be issued)
- Assessment of effects of change
 - Equivalence of impurity profiles
 - Equivalence of physical properties
- Types of change
 - Manufacturing site, scale, or equipment
 - Specifications
 - Manufacturing process
 - Multiple changes
- Regulatory Filings
 - Prior Approval Supplement
 - Changes Being Effected Supplement
 - Annual Report

eje | June 2009

51st Land O'Lakes

52

API Information Requirements

- Manufacturer
- Flow Chart of Synthetic Pathway
- Form / Morphology
- Solubility
- Partition Coefficient
- Intrinsic Dissolution
- PS / PSD
- Bulk & Tap Density
- Water Content / Hygroscopicity
- Microbiological Considerations
- Specifications
- Stability
- Synthetic Impurities
- Degradants
- Potency Factor
- Special Considerations
 - heat, light, moisture, etc.
 - HS&E



eje | June 2009

51st Land O'Lakes

53

Microbiological Considerations

- <61> Microbial Limit Tests
- <71> Sterility Tests
- <85> Bacterial Endotoxins Test
- <151> Pyrogen Test
- <788> Particulate Matter in Injections
- <1111> Microbiological Attributes of Nonsterile Pharmaceutical Products
- <1211> Sterilization and Sterility Assurance of Compendial Articles
- <1227> Validation of Microbial Recovery from Pharmaceutical Articles
- <1231> Water for Pharmaceutical Purposes

eje | June 2009

51st Land O'Lakes

54

Excipient Justifications

- Preservative Level
 - <51> Antimicrobial Effectiveness Testing
 - <341> Antimicrobial Agents - Content
- Antioxidants
 - no compendial tests, but similar expectation
- Concentrations above guidelines
 - FCC limits
 - WHO limits
 - FDA Inactive Ingredients Guide
 - <1074> Excipient Biological Safety Evaluation Guidelines

eje | June 2009

51st Land O'Lakes

55

SUPAC Scale-up and post-Approval Changes

- IR
 - immediate release
- MR
 - modified release
- SS
 - non-sterile semisolids
- PACSAS
 - sterile aqueous solutions
- PAC-ATLS
 - analytical testing lab sites
- Regulatory Filings
 - Prior Approval Supplement
 - Changes Being Effectuated Supplement
 - Annual Report

SUPAC-IR

- Types of Change
 - Level I
 - unlikely to have any detectable impact...
 - Level II
 - could have significant impact...
 - Level III
 - likely to have significant impact...
 - on formulation quality and performance

Change	I	II	III
Components	AR	PAS	PAS+BE
	minor	non-crit	crit
	1 stab	3 accel	3 accel
Site	AR	CBE	CBE
	same	different	different
		(+) data	(-) data
		1 stab	3 accel
Batch Size	AR	CBE	
	<10x pilot	>10x pilot	
	1 stab	1-3 accel	
Equipment	AR	CBE	
	sim oper	different	
	1 stab	1-3 accel	
Process	AR	CBE	PAS
	>val<	<> val	different
		1 stab	1-3 accel



EXTRA SLIDES

Acceptance Criteria



Quality Acceptance Criteria

- Manufacture of Validation Batches
 - Process and Controls Conform to Registration Dossier
 - Process Meets Acceptance Criteria
 - Product Meets Regulatory Specifications
- Commercial Product Equivalence
 - Pilot Scale
 - Clinical Batches
 - Bioequivalence Batch(es)
- cGMP Compliance
 - **Transfers often stop here**

Manufacturing Acceptance Criteria

- Manufacturing Cycle
 - Throughput
 - Time - Single Shift?
 - Cleaning
 - Water / Detergents / Solvents ?
 - Downtime ?
 - Equipment Effectiveness
 - Availability
 - Efficiency
 - Defect Rate
- Cost
- Manufacturing Process
 - Ranges for Processing Parameters
 - Process Yield
 - Minimize Material Waste
 - Process Capability Index
 - Six Sigma Excellence
- Batch Size Flexibility
- Packaging & Labeling
 - multiple configurations and languages

Influence Matrix

Process Step	Process Variables	Responses													Notes:
		Discharge Characteristics	Granulation Quality	Power Load	Moisture Content	Particle Size Distribution	Density	Flow Properties	Density	Uniformity	Fill Weight	Weight Variation	Content Uniformity	Dissolution	
G	Batch Size	S	S	S	?	?	?	N	?	?	?	?	?	N	
G	Speed - main	W	M	S	N	W	W	N	N	N	N	N	N	N	
G	Speed - chopper	M	W	W	N	W	W	N	N	N	N	W	W		S Strong Effect
G	Amount of Water	S	S	M	S	S	S	S	W	S	S	W	S		M Moderate Effect
G	Water Addition Rate	W	S	W	N	W	W	W	M	W	N	N	N		W Weak Effect
G	Granulating Time	S	S	N	N	M	M	M	W	M	S	S			N No Effect
D	Initial Temperature	X	X	X	N	M	N	M	W	N	W	N	N		Y Unknown Effect
D	Drying Temperature	X	X	X	S	W	M	M	N	N	N	N	N		X Not Applicable
D	Air Flow Program	X	X	X	S	W	M	N	N	N	N	N	N		
D	Drying Time	X	X	X	S	W	M	M	N	M	M	N	M		
S	Screen Size	X	X	X	X	S	M	W	W	N	N	N	W		
S	Feed Rate	X	X	X	X	M	W	N	N	N	N	N	N		
B	Loading	X	X	X	X	X	N	N	W	N	N	W	N		
B	Speed	X	X	X	X	X	N	N	W	N	N	N	N		
B	Blending Time	X	X	X	X	X	N	N	S	N	N	S	N		
F	Powder Level	X	X	X	X	X	X	X	X	S	S	N	N		
F	Tamper Settings	X	X	X	X	X	X	X	X	S	S	N	W		
F	Powder Dispersion Aid	X	X	X	X	X	X	X	X	M	M	N	N		

von Doehren et. al., Pharm Tech, 6(9):1982, 145

Confidence Intervals

$$95\% \text{ C.I.} = \text{mean} \pm \frac{t_{0.05} \times \text{Standard Deviation}}{n^{1/2}}$$

$$95\% \text{ C.I.}_{\text{ind}} = \text{mean} \pm \frac{t_{0.05} \times \text{Standard Deviation}}{(n + 1)^{1/2}}$$

- Population parameter with stated confidence
 - Data will be within stated limits 95% of the time
 - Useful for establishing batch record or validation limits

Tolerance Intervals

$$\text{T.I.}_p = \text{mean} \pm (k_{p,\gamma} \times \text{Standard Deviation})$$

- Confidence statement for a coverage of population
 - Interval containing p% of the population - 2 sided
 - p% will not exceed lower (upper) limit - 1 sided
- Wider than Confidence Intervals
 - Useful for predicting the distribution of data within a batch
 - Can be used to guide establishment of regulatory limits

Process Capability Index

$$C_{pk} = \min \left[\frac{\text{Mean} - \text{Lower Limit}}{3 \times \text{Standard Deviation}}, \frac{\text{Upper Limit} - \text{Mean}}{3 \times \text{Standard Deviation}} \right]$$

- < 1.0 Process is Not Capable
- 1.0 - 1.33 Process is Marginal
- 1.34 - 3.0 Process is Good
- > 3.0 Process is Excellent

Miller & Miller, Statistical Methods for Quality with Applications to Engineering and Materials, Prentice-Hall, pp.214-218, 1995.

eje | June 2009 51st Land O'Lakes 64

Process Capability and Process Failure

Batch Failures per Million


C _{pk}	Number of Failures per Million
0.7	10,000
1.0	1,000
1.3	100
1.6	10

A.J.Duncan, Quality Control and Industrial Statistics, Irwin, p.456, 1986.

eje | June 2009 51st Land O'Lakes 65

Process Capability for Technology Transfer

C_{pk} Targets



eje | June 2009

51st Land O'Lakes

66

Cautions for Using C_{pk}

- Statistical control should be achieved before using C_{pk}
- Data must approximate a normal distribution
- Can underestimate effects if not enough data are available
- Non-representative sampling may result in high estimates of C_{pk}
- Treats both ends of the specification equally
- Only as good as the specifications on which it is based
- Not a summary parameter (can not be averaged)
- Can not separate sampling/testing error from process error
- Focus on reducing variability rather than C_{pk}
- Could result in wider specifications than necessary

eje | June 2009

51st Land O'Lakes

67

Six Sigma


- Business philosophy
 - eliminate defects through fundamental process knowledge
- Business, statistical and engineering tools
 - reduce costs through self-funded improvement
 - reduce waste
 - better understand customer requirements
 - improve delivery and quality performance
 - provide critical process inputs to respond to changing customer requirements
 - develop robust processes and products
 - drive rapid improvement

eje | June 2009

51st Land O'Lakes

68

Six Sigma Performance



- 99.9997%
- Why 99% is not good enough...
 - 30 spelling mistakes per page
 - 20,000 letters lost daily
 - 15 minutes of electrical failure per day
 - 2 crash landings daily at each major airport globally

eje | June 2009

51st Land O'Lakes

69


Lean Manufacturing

- Tools to reduce waste and streamline operations
 - reduce waste
 - reduce inventory and floor space
 - create more robust production systems
 - develop appropriate material delivery systems
 - improve layouts for increased flexibility

Responsibilities Matrix


Project Task	Group Responsible for Task Completion									
	Form	TT	DV	AS	CQA	PE	QA	QAV	MF	QAS
Issue process/formulation comparison report	N	P				I				I
Complete manufacturing master batch record	N	N,S				P,A	A	A	A	
Issue technical transfer document	N,A	P,A	N	N		N,A	A	N,A	I,A	
Generate validation master plan/protocols	I	N,A	N			N,A		P,A	A	A
FDA pre-approval inspection	N	N	N	N	N	N	P	N	N	N
Manufacture validation batches	I	N				N	S	N	P	S
Issue validation report	I	N,A				N,A	A	P,A	A	A

P = Primary Responsibility
N = Input Required
A = Approval
I = Informed
S = Support




Extra Slides

Validation



**SCHOOL OF
PHARMACY**
University of Wisconsin-Madison




Extension Services in Pharmacy
University of Wisconsin - Madison
School of Pharmacy

eje | June 2009
51st Land O'Lakes
72

Quality Systems

- SPC
 - Histograms
 - Check Sheets
 - Pareto Charts
 - Cause and Effect Diagrams
 - Fishbone
 - Ishikawa
 - Defect Concentration Diagrams
 - Scatter Diagrams
 - Control Charts

- SQC
 - Quality Circles
 - TQM / TQC
 - Quality One (Q1)
 - ISO 9000...
 - JIT
 - Six Sigma
 - MAIC
 - DFSS
 - Lean Manufacturing



eje | June 2009
51st Land O'Lakes
73

FDA: "Process Validation"

"Process validation is establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its pre-determined specifications and quality characteristics."

From FDA's "GUIDELINE ON GENERAL PRINCIPLES OF PROCESS VALIDATION," May 1987

Process Validation

VIII. ELEMENTS OF PROCESS VALIDATION

- A. Prospective Validation
 - 1. Equipment and Process
 - a. Equipment : Installation Qualification
 - b. Process: Performance Qualification
 - c. Product: Performance Qualification
 - 2. System to Assure Timely Revalidation
 - 3. Documentation
- B. Retrospective Process Validation

From FDA's "GUIDELINE ON GENERAL PRINCIPLES OF PROCESS VALIDATION," May 1987

Conducting Process Validation

- **Three-batch validation** at end of development, i.e. in commercial production site
- Focus on facilities, equipment, components, methods, process qualification
- PV execution thereby provides the necessary documentation to show product reproducibility, and a process under control

Note: *Failure* to execute PV successfully reflects incomplete understanding of the process